14:08:49 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2022-08-25 08:30:00
Bergen, 25 August 2022. 

Today, Lifecare present strong financial results following the first half-year
with operational activities in two German subsidiaries as part of the Lifecare
Group. The external revenue in 1H 2022 reached a total of 8,7MNOK, representing
an increase of +8,7MNOK from 1H 2021 (from 0,0 MNOK) and +7,1MNOK from EY 2021
(from 1,6MNOK). A steep increase in operational activities in the Lifecare Group
led to increases in salaries and other operational activities.

The successful integration of operational subsidiaries in Germany has led to
increased operational capacity. The restructured organization has proved its
capacity and efficiency achieving the major technical milestones of (1)
reproducible and stable in-vitro testing of miniaturized prototype-sensors and
(2) initiation of first-in-human clinical pilot study, as announced in June
2022.

Lifecare's semi-annual report is available for downloading here:
https://lifecare.no/reports/semi-annual-report-2022/

Lifecare AS will host an online presentation of the 1H 2022 semi-annual results
today (25 August) at 13:00 - 14:00 CET. All shareholders and other interested
parties are welcome to participate in the webcast. Lifecare CEO Joacim Holter
will present H1 2022 financial results and company status and will together with
Lifecare CSO Prof. Andreas Pfützner be available in a Q&A session following the
presentation.

The webcast will be available here:
https://teams.microsoft.com/l/meetup-join/19%3ameeting_Mzg3OTJmNDUtMmVmYS00NWZhL
TkzMjctOTFiNWZmZTZhYTk2%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45
db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%22e067d101-8c82-4495-b6ce-29a800accfd6%22
%7d

Questions can be posted during the event or send in advance to: post@lifecare.no

Contact:
Joacim Holter, CEO, tel. +47 40059050, epost: joacim.holter@lifecare.no


This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act. This stock exchange announcement was
published by Joacim Holter, Lifecare CEO, on 25 August 2022 at 08:30 CET.